Key Highlights:
- Biostate AI announced that its Indian subsidiary Bayosthiti AI has partnered with Narayana Health to develop AI models designed specifically to predict cardiovascular disease in Indian populations, addressing a major gap in global risk tools that are largely based on Western patient data.
- The collaboration will analyze molecular data from 12,000 patients treated at the Narayana Institute of Cardiac Sciences, focusing on full RNA transcriptome profiles to identify early biological signals of disease. South Asians often develop heart disease 5–10 years earlier than Western populations, making population-specific diagnostics critical for earlier detection.
- The initiative leverages Biostate AI’s proprietary BIRT Technology and AI models to analyze millions of RNA expressions, potentially identifying high-risk patients 2–3 years before traditional diagnostic methods. If validated, the program could lead to a scalable blood-based diagnostic test for coronary artery disease across India and other South Asian populations.
Implications:
India-specific models target the $1.68B cardiovascular devices/diagnostics market (8.5% CAGR to $2.53B by 2031), shifting Narayana’s 60K+ annual procedures toward prevention.
RNA-AI could reduce India’s 2.5M heart deaths by 15-20%, disrupting lipid/ECG dominance and attracting PE to molecular cardiac platforms.
Validation cements Bengaluru as CVD-AI hub, exporting to Saudi/Gulf amid demographic parallels.
Source: Businesswire
No Comment! Be the first one.